Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Use of /sup 131/I-MIBG scintigraphy in the evaluation of suspected pheochromocytoma

Journal Article · · Mayo Clin., Proc.; (United States)
Studies at the University of Michigan have shown that /sup 131/I-metaiodobenzylguanidine (/sup 131/I-MIBG) is an effective agent for the diagnosis and localization of pheochromocytomas and paragangliomas. The authors conducted a study that confirmed and expanded that finding. From January 1983 to March 1984, 48 patients at our institution had 51 /sup 131/I-MIBG scans during the workup of suspected sporadic or metastatic pheochromocytoma. Scintigrams were obtained after 500 microCI of /sup 131/I-MIBG had been administered intravenously. The final diagnosis (true-positive, false-negative, or false-positive result) was made at operation and pathologic examination. A true-negative diagnosis was confirmed by normal plasma and fractionated urinary levels of catecholamines and metabolites and, in most patients, computed tomography (CT). The overall sensitivity of /sup 131/I-MIBG scanning was 77%, specificity was 96%, and accuracy was 86%. This test is fairly sensitive in the workup of patients with known or suspected recurrent or metastatic pheochromocytoma. It may also be helpful in the evaluation of suspected sporadic pheochromocytoma when CT findings are normal.
Research Organization:
Mayo Graduate School of Medicine, Rochester, MN
OSTI ID:
5126544
Journal Information:
Mayo Clin., Proc.; (United States), Journal Name: Mayo Clin., Proc.; (United States) Vol. 5; ISSN MACPA
Country of Publication:
United States
Language:
English